Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective - LC-MS in Drug Bioanalysis - page 214

Table 2 (continued)

Volume of biological
sample

Accuracy at LOQ
(% bias)

Precision at LOQ
(CV%) Drugs analyzed Analytical method LOQ (ng/ml) Reference

Ge fi tinib, erlotinib,
sunitinib and
sorafenib

20 ml Human whole blood,
serum, plasma and cell
culture medium

Turbo ion
spray-TSQ

5 3.7 to 13.5 1.9 to 12 Honeywell et al. [ 136 ]

Imatinib PBMC ESI-TSQ 10 - - Widmer et al. [ 42 ]

Nilotinib, dasatinib,
and bosutinib

2 × 10 6 K562 cells ESI-TSQ 0.1-1 - - Hegedus et al. [ 142 ]

Imatinib, nilotinib,
dasatinib,
sunitinib,
and sorafenib

9 × 10 5 K562 cells ESI-TSQ 1-10 −12.6 to 10.1 % 9.1 to 11.3 % Haouala et al. [ 143 ]

Imatinib, dasatinib,
and nilotinb

PBMC HPLC-MS 0.25 ng D'Avolio et al. [ 144 ]